[8-K] Hawkins Inc Reports Material Event

Rhea-AI Filing Summary

Paradigm BioCapital Advisors LP, its general partner, founder Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. jointly filed a Schedule 13G reporting passive ownership of 1,128,613 Cidara Therapeutics (CDTX) common shares as of 23 Jul 2025.

This holding equals 5.6 % of the 20,163,696 shares outstanding (per the issuer’s 25 Jun 2025 prospectus supplement), crossing the 5 % threshold that mandates disclosure. The Cayman-based Fund directly owns 994,177 shares (4.9 %), with the balance held in separately managed accounts advised by Paradigm. All shares are subject to sole voting and dispositive power; no shared power is reported.

The stake is filed under Rule 13d-1(c); the certification states the securities were not acquired to influence or change control. Signatures were executed on 30 Jul 2025 by authorized signatory David K. Kim. No additional agreements, transactions, or control intentions are disclosed.

Positive

• Paradigm BioCapital disclosed ownership of 5.6 % of CDTX, adding a specialized healthcare investor to the shareholder base.
• All reported shares are under sole voting and dispositive power, indicating clear ownership structure without complex arrangements.

Negative

• The stake is filed on Schedule 13G, signaling no intent to influence control, so immediate strategic benefits for other shareholders are limited.

Insights

Financial Analyst

TL;DR: Paradigm discloses a 5.6 % passive stake—incremental validation, limited strategic impact.

The filing signals that a life-sciences–focused hedge fund has accumulated a meaningful but non-controlling position in CDTX. A 5.6 % stake demonstrates confidence in the company’s prospects, yet the Schedule 13G (vs. 13D) and explicit certification confirm a passive intent, reducing expectations of activism. The bulk of shares (4.9 %) reside in the offshore fund, implying limited liquidity constraints. While institutional ownership can support share price stability, the position alone does not materially alter governance or capital structure. Overall impact to valuation is modest.

Corporate Governance Specialist

TL;DR: Ownership below control thresholds; governance implications minimal.

Because Paradigm’s stake is below 10 % and filed on a 13G, the group avoids filing obligations tied to intent to influence control (e.g., proxy contests). Sole voting power suggests no complicated voting arrangements. The absence of group formation or board-related provisions means current governance dynamics remain unchanged. Investors should monitor future filings for any conversion to a 13D, which would indicate a strategic shift.

0000046250FALSE00000462502025-07-302025-07-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 30, 2025

Hawkins, Inc.

(Exact name of registrant as specified in its charter)

 

Minnesota

0-7647

41-0771293

(State of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2381 Rosegate,

Roseville,

Minnesota

55113

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code (612) 331-6910

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $.01 per share			HWKN			Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b 2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On July 30, 2025, Hawkins, Inc. issued a press release announcing financial results for its fiscal 2026 first quarter ended June 29, 2025. A copy of the press release issued by the Registrant is furnished herewith as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.

Description

Method of Filing

99.1

Press Release, dated July 30, 2025, announcing financial results of Hawkins, Inc. for its fiscal 2026 first quarter ended June 29, 2025.

Filed Electronically

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

Filed Electronically

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HAWKINS, INC.

Date: July 30, 2025

By:

/s/ Jeffrey P. Oldenkamp

Jeffrey P. Oldenkamp

Executive Vice President and Chief Financial Officer

FAQ

How many Cidara Therapeutics (CDTX) shares does Paradigm BioCapital own?

1,128,613 common shares as of 23 Jul 2025.

What percentage of CDTX’s outstanding stock is represented by Paradigm’s holding?

The filing lists 5.6 % of the 20.16 m shares outstanding.

Who are the reporting persons in the Schedule 13G?

Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd.

Is Paradigm seeking to influence control of Cidara Therapeutics?

No. The Schedule 13G includes a certification of passive intent under Rule 13d-1(c).

When was the Schedule 13G event date and filing date?

Event date: 23 Jul 2025; signatures dated 30 Jul 2025.